Efficiency and safety of phenylephrine and tropicamide used in premature retinopathy: a prospective observational study

Atilla Alpay, Sılay Canturk Ugurbas, Cumhur Aydemir, Atilla Alpay, Sılay Canturk Ugurbas, Cumhur Aydemir

Abstract

Background: To determine effects and side effects of topical application of phenylephrine 2.5% and tropicamide 0.5% combination in preterm infants.

Methods: In this prospective observational study, 60 infants undergoing retinopathy of prematurity (ROP) screening were prospectively observed. Pupillary diameter, blood pressure, heart rate, and oxygen saturation were monitored before and after up to 24 h during ROP screening examinations.

Results: The mean pupillary diameter 1 h after the instillation of drops was 5.58 ± 0.75 mm for both eyes. The mean systolic and diastolic pressure and oxygen saturation of infants did not change statistically until the end of the study. The average heart rate decreased by a mean of 4.96 beats/minute from the baseline following eye drops instillation. General condition deterioration, fall in oxygen saturation and bradycardia were observed in 4 infants that already had respiratory distress syndrome.

Conclusion: The phenylephrine 2.5% plus tropicamide 0.5% drop is effective and safe as mydriatic combination for retinopathy of prematurity screening. In infants with an additional systemic disease such as respiratory distress syndrome, the side effects of mydriatic drops may be more common. Such babies should be kept under close observation.

Trial registration: The trial was retrospectively registered on 28 February 2018. The ClinicalTrials.gov Identifier is NCT03448640.

Keywords: Adverse events; Mydriatics; Retinopathy of prematurity; Screening.

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
Mean systolic and diastolic blood pressure changes during the study. Thin arrows; shows the time of instillation of eye drops immediately after taking vital values. Bold arrow; shows the time of fundus examination immediately after taking vital values
Fig. 2
Fig. 2
Mean pulse rate during the study. Thin arrows; shows the time of instillation of eye drops immediately after taking vital values. Bold arrow; shows the time of fundus examination immediately after taking vital values
Fig. 3
Fig. 3
Median oxygen saturation during the study. Thin arrows; shows the time of instillation of eye drops immediately after taking vital values. Bold arrow; shows the time of fundus examination immediately after taking vital values

References

    1. Spencer R. Long-term visual outcomes in extremely low-birth-weight children (an American ophthalmological society thesis) Trans Am Ophthalmol Soc. 2006;104:493–516.
    1. Dhingra D, Katoch D, Dutta S, Samanta R, Aggarwal K, Dogra MR. Change in the incidence and severity of retinopathy of prematurity (ROP) in a neonatal intensive care unit in northern India after 20 years: comparison of two similar prospective cohort studies. Ophthalmic Epidemiol. 2019;26(3):169–174. doi: 10.1080/09286586.2018.1562082.
    1. Chew C, Rahman RA, Shafie SM, Mohamad Z. Comparison of mydriatic regimens used in screening for retinopathy of prematurity in preterm infants with dark irides. J Pediatr Ophthalmol. 2005;42(3):166–173.
    1. Sindel BD, Baker MD, Maisels MJ, Weinstein J. A comparison of the pupillary and cardiovascular effects of various mydriatic agents in preterm infants. J Pediatr Ophthalmol Strabismus. 1986;23(6):273–276.
    1. Rosales T, Isenberg S, Leake R, Everett S. Systemic effects of Mydriatics in low weight infants. J Pediatr Ophthalmol. 1981;18(6):42–44.
    1. Clarke WN, Hodges E, Noel LP, Roberts D, Coneys M. The oculocardiac reflex during ophthalmoscopy in premature infants. Am J Ophthalmol. 1985;99(6):649–651. doi: 10.1016/S0002-9394(14)76029-5.
    1. Lees BJ, Cabal LA. Increased blood pressure following pupillary dilation with 2.5% phenylephrine hydrochloride in preterm infants. Pediatrics. 1981;68(2):231–234.
    1. Isenberg S, Everett S, Parelhoff E. A comparison of mydriatic eyedrops in low-weight infants. Ophthalmology. 1984;91(3):278–279. doi: 10.1016/S0161-6420(84)34303-2.
    1. Alpay A, Ermis B, Ugurbas SC, Battal F, Sagdik HM. The local vasoconstriction of infant's skin following instillation of mydriatic eye drops. Eur J Clin Pharmacol. 2010;66(11):1161–1164. doi: 10.1007/s00228-010-0890-6.
    1. Khoo BK, Koh A, Cheong P, Ho NK. Combination cyclopentolate and phenylephrine for mydriasis in premature infants with heavily pigmented irides. J Pediatr Ophthalmol Strabismus. 2000;37(1):15–20.
    1. Lux AL, Degoumois A, Barjol A, Mouriaux F, Denion E. Combination of 5% phenylephrine and 0.5% tropicamide eyedrops for pupil dilation in neonates is twice as effective as 0.5% tropicamide eyedrops alone. Acta Ophthalmol. 2016.
    1. Trinavarat A, Pituksung A. Effective pupil dilatation with a mixture of 0.75% tropicamide and 2.5% phenylephrine: a randomized controlled trial. Indian J Ophthalmol. 2009;57(5):351–354. doi: 10.4103/0301-4738.55070.
    1. Bolt B, Benz B, Koerner F, Bossi E. A Mydriatic eye-drop combination without systemic effects for premature-infants - a prospective double-blind-study. J Pediatr Ophthalmol. 1992;29(3):157–162.
    1. Merritt JC, Kraybill EN. Effect of Mydriatics on blood-pressure in premature-infants. J Pediatr Ophthalmol. 1981;18(5):42–46.
    1. Gray C. Systemic toxicity with topical ophthalmic medications in children. Paed Perinat Drug Ther. 2006;7:23–29. doi: 10.1185/146300905X75334.
    1. Ogut MS, Bozkurt N, Ozek E, Birgen H, Kazokoglu H, Ogut M. Effects and side effects of mydriatic eyedrops in neonates. Eur J Ophthalmol. 1996;6(2):192–196. doi: 10.1177/112067219600600218.
    1. Young T. Pharmacology review: topical mydriatics: the adverse effects of screening examinations for retinopathy of prematurity. NeoReviews. 2003;4(6):163–166. doi: 10.1542/neo.4-6-e163.
    1. Lim DL, Batilando M, Rajadurai VS. Transient paralytic ileus following the use of cyclopentolate-phenylephrine eye drops during screening for retinopathy of prematurity. J Paediatr Child Health. 2003;39(4):318–320. doi: 10.1046/j.1440-1754.2003.00144.x.
    1. Mitchell AJ, Green A, Jeffs DA, Roberson PK. Physiologic effects of retinopathy of prematurity screening examinations. Adv Neonatal Care. 2011;11(4):291–297. doi: 10.1097/ANC.0b013e318225a332.
    1. Bonthala S, Sparks JW, Musgrove KH, Berseth CL. Mydriatics slow gastric emptying in preterm infants. J Pediatr. 2000;137(3):327–330. doi: 10.1067/mpd.2000.107842.
    1. Patel AJ, Simon JW, Hodgetts DJ. Cycloplegic and mydriatic agents for routine ophthalmologic examination: a survey of pediatric ophthalmologists. J AAPOS. 2004;8(3):274–277. doi: 10.1016/j.jaapos.2004.01.004.
    1. Chien DS, Homsy JJ, Gluchowski C, Tang-Liu DD. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr Eye Res. 1990;9(11):1051–1059. doi: 10.3109/02713689008997579.
    1. Rush R, Rush S, Nicolau J, Chapman K, Naqvi M. Systemic manifestations in response to mydriasis and physical examination during screening for retinopathy of prematurity. Retina. 2004;24(2):242–245. doi: 10.1097/00006982-200404000-00009.
    1. Laws DE, Morton C, Weindling M, Clark D. Systemic effects of screening for retinopathy of prematurity. Br J Ophthalmol. 1996;80(5):425–428. doi: 10.1136/bjo.80.5.425.
    1. Neffendorf JE, Mota PM, Xue K, Hildebrand GD. Efficacy and safety of phenylephrine 2.5% with cyclopentolate 0.5% for retinopathy of prematurity screening in 1246 eye examinations. Eur J Ophthalmol. 2015;25(3):249–253. doi: 10.5301/ejo.5000540.
    1. Thanathanee O, Ratanapakorn T, Morley MG, Yospaiboon Y. Lower conjunctival fornix packing for mydriasis in premature infants: a randomized trial. Clin Ophthalmol. 2012;6:253–256.
    1. Mitchell A, Hall RW, Erickson SW, Yates C, Hendrickson H. Systemic absorption of Cyclopentolate and adverse events after retinopathy of prematurity exams. Curr Eye Res. 2016;41(12):1601–1607. doi: 10.3109/02713683.2015.1136419.
    1. Cohen AM, Cook N, Harris MC, Ying GS, Binenbaum G. The pain response to mydriatic eyedrops in preterm infants. J Perinatol. 2013;33(6):462–465. doi: 10.1038/jp.2012.149.
    1. Ballabh P. Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res. 2010;67(1):1–8. doi: 10.1203/PDR.0b013e3181c1b176.
    1. Anand KJ. Clinical importance of pain and stress in preterm neonates. Biol Neonate. 1998;73(1):1–9. doi: 10.1159/000013953.
    1. Belda S, Pallas CR, De la Cruz J, Tejada P. Screening for retinopathy of prematurity: is it painful? Biol Neonate. 2004;86(3):195–200. doi: 10.1159/000079542.
    1. Wilkinson AR, Haines L, Head K, Fielder AR. UK retinopathy of prematurity guideline. Early Hum Dev. 2008;84(2):71–74. doi: 10.1016/j.earlhumdev.2007.12.004.
    1. Ophthalmic Drug Comparison: Tropicamide 1% vs. Cyclopentolate 1% Effects on Accommodative Recovery.
    1. Barlett JD, Jaanus SD. Clinical ocular pharmacology, 4 edn; 2001.
    1. Sesham R, Puvanachandra N, Muthukumar P. Phenylephrine eye drops: a rare complication in preterm neonate. Arch Dis Child Fetal Neonatal Ed. 2014;99(3):F180. doi: 10.1136/archdischild-2013-305485.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe